- Home
- XBIO
as 05-16-2025 4:00pm EST
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | FRAMINGHAM |
| Market Cap: | 4.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 9.5K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.20 - $5.20 | Next Earning Date: | 05-13-2025 |
| Revenue: | $2,582,728 | Revenue Growth: | 5.63% |
| Revenue Growth (this year): | 14.23% | Revenue Growth (next year): | -17.86% |
Latest Xenetic Biosciences Inc. News
XBIO Breaking Stock News: Dive into XBIO Ticker-Specific Updates for Smart Investing
ACCESS Newswire
2 days ago
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Associated Press Finance
3 days ago
Xenetic Biosciences: Q1 Earnings Snapshot
ACCESS Newswire
a month ago
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
ACCESS Newswire
2 months ago
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Simply Wall St.
2 months ago
Xenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
ACCESS Newswire
2 months ago
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
ACCESS Newswire
2 months ago
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
ACCESS Newswire
3 months ago
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
Compare XBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XBIO Xenetic Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.